{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T20:43:41Z","timestamp":1793133821851,"version":"4.5.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,7]],"date-time":"2020-12-07T00:00:00Z","timestamp":1607299200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006396","name":"Alexion Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006396","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.kint.2020.10.046","type":"journal-article","created":{"date-parts":[[2020,12,8]],"date-time":"2020-12-08T12:02:55Z","timestamp":1607428975000},"page":"225-237","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":97,"title":["The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome na\u00efve to complement inhibitor treatment"],"prefix":"10.1016","volume":"100","author":[{"given":"Gema","family":"Ariceta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley P.","family":"Dixon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seong Heon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaurav","family":"Kapur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teri","family":"Mauch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Ortiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Vallee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew E.","family":"Denker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hee Gyung","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2490-021X","authenticated-orcid":false,"given":"Larry A.","family":"Greenbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Lovell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Muff-Luett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Malone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oluwasegun","family":"Adeagbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandria","family":"Wilkerson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria","family":"Fraga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scherezade","family":"Sarri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hae Il","family":"Cheong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yo Han","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoung Hee","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.kint.2020.10.046_bib1","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0140-6736(17)30062-4","article-title":"Haemolytic uraemic syndrome","volume":"390","author":"Fakhouri","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2020.10.046_bib2","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.kint.2016.10.005","article-title":"Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a \"Kidney Disease: Improving Global Outcomes\" (KDIGO) Controversies Conference","volume":"91","author":"Goodship","year":"2017","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2020.10.046_bib3","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.2215\/CJN.02210310","article-title":"Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype","volume":"5","author":"Noris","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2020.10.046_bib4","doi-asserted-by":"crossref","first-page":"554","DOI":"10.2215\/CJN.04760512","article-title":"Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults","volume":"8","author":"Fremeaux-Bacchi","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2020.10.046_bib7","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.kint.2015.11.026","article-title":"Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome","volume":"89","author":"Greenbaum","year":"2016","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2020.10.046_bib8","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/s10157-018-1610-2","article-title":"Safety and effectiveness of eculizumab for pediatric patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance","volume":"23","author":"Ito","year":"2019","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.kint.2020.10.046_bib9","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00467-015-3076-8","article-title":"An international consensus approach to the management of atypical hemolytic uremic syndrome in children","volume":"31","author":"Loirat","year":"2016","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.kint.2020.10.046_bib10","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.tmrv.2019.09.004","article-title":"Eculizumab and beyond: the past, present, and future of complement therapeutics","volume":"33","author":"Patriquin","year":"2019","journal-title":"Transfus Med Rev"},{"key":"10.1016\/j.kint.2020.10.046_bib11","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1016\/S0149-2918(03)80222-9","article-title":"The impact of reducing dose frequency on health outcomes","volume":"25","author":"Richter","year":"2003","journal-title":"Clin Ther"},{"key":"10.1016\/j.kint.2020.10.046_bib12","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s00277-016-2867-8","article-title":"Development of a disease-specific quality of life questionnaire for patients with aplastic anemia and\/or paroxysmal nocturnal hemoglobinuria (QLQ-AA\/PNH)-report on phases I and II","volume":"96","author":"Groth","year":"2017","journal-title":"Ann Hematol"},{"key":"10.1016\/j.kint.2020.10.046_bib13","first-page":"527","article-title":"Dosing frequency and medication adherence in chronic disease","volume":"18","author":"Coleman","year":"2012","journal-title":"J\u00a0Manag Care Pharm"},{"key":"10.1016\/j.kint.2020.10.046_bib14","series-title":"Ravulizumab prescribing information","year":"2018"},{"key":"10.1016\/j.kint.2020.10.046_bib15","series-title":"Ravulizumab summary of product characteristics","author":"EMA","year":"2019"},{"key":"10.1016\/j.kint.2020.10.046_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0195909","article-title":"Design and preclinical characterization of ALXN1210: a novel anti-C5 antibody with extended duration of action","volume":"13","author":"Sheridan","year":"2018","journal-title":"PloS One"},{"key":"10.1016\/j.kint.2020.10.046_bib17","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.kint.2020.01.035","article-title":"The long-acting C5 inhibitor, ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome na\u00efve to complement inhibitor treatment","volume":"97","author":"Rondeau","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2020.10.046_bib18","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0885-3924(02)00529-8","article-title":"Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales","volume":"24","author":"Cella","year":"2002","journal-title":"J\u00a0Pain Symptom Manage"},{"key":"10.1016\/j.kint.2020.10.046_bib19","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome","volume":"368","author":"Legendre","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2020.10.046_bib20","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1053\/j.ajkd.2015.12.034","article-title":"Terminal complement inhibitor eculizumab in adult patients with atypical hemolytic uremic syndrome: a single-arm, open-label trial","volume":"68","author":"Fakhouri","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2020.10.046_bib21","first-page":"8565498","article-title":"Assessment of quality of life among children with end-stage renal disease: a cross-sectional study","volume":"2018","author":"El Shafei","year":"2018","journal-title":"J\u00a0Environ Public Health"},{"key":"10.1016\/j.kint.2020.10.046_bib22","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1007\/s11136-018-1789-4","article-title":"Children on dialysis as well as renal transplanted children report severely impaired health-related quality of life","volume":"27","author":"Splinter","year":"2018","journal-title":"Qual Life Res"},{"key":"10.1016\/j.kint.2020.10.046_bib23","first-page":"1","article-title":"KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"3","year":"2013","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.kint.2020.10.046_bib24","first-page":"27","article-title":"An update for atypical haemolytic uraemic syndrome: diagnosis and treatment: a consensus document","volume":"33","author":"Campistol","year":"2013","journal-title":"Nefrologia"},{"key":"10.1016\/j.kint.2020.10.046_bib25","doi-asserted-by":"crossref","first-page":"3253","DOI":"10.1182\/blood-2014-09-600411","article-title":"Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS","volume":"125","author":"Cofiell","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.kint.2020.10.046_bib26","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1007\/s00467-018-4039-7","article-title":"Extra-renal manifestations of atypical hemolytic uremic syndrome","volume":"34","author":"Cassandra Formeck","year":"2019","journal-title":"Pediatric Nephrol"},{"key":"10.1016\/j.kint.2020.10.046_bib27","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.ekir.2020.05.003","article-title":"Functional assessment of fatigue and other patient-reported outcomes in patients enrolled in the Global aHUS Registry","volume":"5","author":"Greenbaum","year":"2020","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2020.10.046_bib28","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/hae.13624","article-title":"Health-related quality of life in paediatric haemophilia B patients treated with rIX-FP","volume":"25","author":"von Mackensen","year":"2019","journal-title":"Haemophilia"},{"issue":"suppl 3","key":"10.1016\/j.kint.2020.10.046_bib29","doi-asserted-by":"crossref","first-page":"S841","DOI":"10.1016\/j.jval.2019.09.2337","article-title":"Comparing productivity losses from treating atypical hemolytic uremic syndrome patients in the United States with eculizumab or ravulizumab in an infusion clinic or at home [PR05]","volume":"22","author":"Levy","year":"2019","journal-title":"Value Health"},{"key":"10.1016\/j.kint.2020.10.046_bib30","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/bjh.15790","article-title":"Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10-year pharmacovigilance analysis","volume":"185","author":"Socie","year":"2019","journal-title":"Br J Haematol"},{"issue":"suppl 75","key":"10.1016\/j.kint.2020.10.046_bib32","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1182\/blood-2019-122421","article-title":"Discordance between free C5 and CH50 complement assays in measuring complement C5 inhibition in patients with aHUS treated with ravulizumab","volume":"134","author":"Cataland","year":"2019","journal-title":"Blood"}],"updated-by":[{"DOI":"10.1016\/j.kint.2023.04.010","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000}}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253820314186?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253820314186?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,6,20]],"date-time":"2023-06-20T02:37:53Z","timestamp":1687228673000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253820314186"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["S0085253820314186"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2020.10.046","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome na\u00efve to complement inhibitor treatment","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2020.10.046","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}